Abstract 3090
Background
Using comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) we compared the frequency of IO biomarkers in ACB, UBC and SCCB. We also report the interim results of neoadjuvant pembrolizumab in patients (pts) with muscle-invasive bladder cancer (MIBC) and variant histologies from PURE01 (NCT02736266).
Methods
Within FMI database, 143 cases of ACB, 2,142 cases of UCB and 83 cases of SCCB were subjected to CGP using a hybrid-capture based assay. Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci. PD-L1 expression was determined by IHC using the Ventana SP-142 assay with >1% tumor cell or immunocyte (TILs) scoring positive. Among 96 pts of PURE01, 15 had predominant variant SCCB histology.
Results
ACB patients were younger and more often female than UBC and SCCB (P < 0.0001). UBC and SCCB had a higher genomic alterations per tumor (GA/tumor) than ACB (P = 0.01). The UBC and SCCB had a significantly higher TMB than ACB (P < 0.0001) including mean TMB and TMB >/= 20 mut/Mb (P < 0.0001). CD274(PD-L1) was amplified more frequently in SCCB than ACB or UBC (P < 0.0001). MSI high status was very uncommon in all tumor types. The frequencies of PD-L1 expression in both tumor cells and TILs was higher in UBC and SCCB than in ACB (P < 0.0001). In PURE01, 5 SCCB (33.3%) achieved pT0 response, and 10 (66.7%) a pT < 2 response.Table:
930P
Adenocarcinoma (ACB) | Urothelial Carcinoma (UBC) | Squamous Cell Carcinoma (SCCB) | |
---|---|---|---|
Cases | 143 | 2,142 | 83 |
Median Age (Range) In years | 58 (24-83) | 67 (19-88) | 62 (31-88) |
Males/Females | 57/86 | 1597/545 | 45/38 |
GA/tumor | 5.4 | 7.7 | 8.2 |
MSI High | 2/106 (2%) | 11/1661 (1%) | 1/69 (1%) |
CD274 (PD-L1) gene amplification | 0 (0%) | 17 (1%) | 4 (5%) |
Mean TMB | 2.4 mut/Mb | 9.9 mut/Mb | 10.4 mut/Mb |
TMB >/= 10 mut/Mb | 14 (10%) | 697 (32%) | 26 (31%) |
TMB >/= 20 mut/Mb | 4 (3%) | 243 (11%) | 13 (16%) |
PD-L1 IHC Positive Tumor Cells | 2/11 (18%) | 76/244 (31%) | 3/10 (30%) |
PD-L1 IHC Positive TILs | 0/11 (0%) | 74/244 (29%) | 3/10 (30%) |
Conclusions
Deep sequencing reveals significant differences in IO biomarkers among the 3 major types of bladder carcinomas. UBC and SCCB have higher frequencies of high TMB and PD-L1 expression than ACB and SCCB has the highest frequency of CD274amplification. Neoadjuvant pembrolizumab showed preliminary activity in SCCB. Further study of IO biomarkers in coordination with therapy response and inclusion of SCCB appear warranted in perioperative IO trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Foundation Medicine.
Funding
Foundation Medicine.
Disclosure
J.S. Ross: Full / Part-time employment: Foundation Medicine. S.M. Ali: Full / Part-time employment: Foundation Medicine. J. Chung: Full / Part-time employment: Foundation Medicine. A.B. Schrock: Full / Part-time employment: Foundation Medicine. R. Madison: Full / Part-time employment: Foundation Medicine. B.M. Alexander: Full / Part-time employment: Foundation Medicine. A. Necchi: Advisory / Consultancy: Merck; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (institution), Advisory / Consultancy: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
3290 - Identification of meningioma patients in high risk of tumor recurrence using microRNA profiling
Presenter: Josef Srovnal
Session: Poster Display session 3
Resources:
Abstract
2477 - Antecedent of cancer and mortality after the first ST segment elevation acute myocardial infarction treated with primary coronary angioplasty. A prospective cohort study
Presenter: Irene Sillero
Session: Poster Display session 3
Resources:
Abstract
1894 - Genomic characterisation of locally advanced pancreatic adenocarcinoma
Presenter: Sarah Picardo
Session: Poster Display session 3
Resources:
Abstract
3280 - Comparison of freshly prepared and frozen cells from colorectal cancer surgical samples for phenotyping experiments- a pilot study
Presenter: Sandra Mersakova
Session: Poster Display session 3
Resources:
Abstract
3419 - Hyaluronan (HA) Accumulation in the Tumor Microenvironment (TME) is Increased in Colorectal Cancer (CRC) and Associated with Consensus Molecular Subtypes (CMS) 4 Molecular Subtype
Presenter: Barbara Blouw
Session: Poster Display session 3
Resources:
Abstract
1833 - Evaluation of CT-based radiomics in patients with renal cell carcinoma
Presenter: An Zhao
Session: Poster Display session 3
Resources:
Abstract
5883 - Detection of Double Protein Expression in Diffuse Large B Cell Lymphoma
Presenter: Mohamed Gouda
Session: Poster Display session 3
Resources:
Abstract
5415 - Encyclopedic Tumor Analysis for organ agnostic treatment with Axitinib in combination regimens for advanced cancers
Presenter: Tim Crook
Session: Poster Display session 3
Resources:
Abstract
3297 - Computational model to predict response rate of clinical trials
Presenter: Orsolya Lorincz
Session: Poster Display session 3
Resources:
Abstract
4355 - Analysis of BRCA genes and homologous recombination deficiency (HRD) scores in tumours from patients (pts) with metastatic breast cancer (mBC) in the OlympiAD trial
Presenter: Mark Robson
Session: Poster Display session 3
Resources:
Abstract